Medical News

[ Hypernasal Speech And Nasal Air Escape Associated With Wider Cleft Palate ]

Hypernasal Speech And Nasal Air Escape Associated With Wider Cleft Palate

According to a study published Online First in Archives of Facial Plastic Surgery, patients with wider cleft palates seem to have an increased risk of developing hyper nasal speech and nasal air escape during speaking (velopharyngeal insufficiency or VPI) after surgery. The study's background information states that about one of 2, 000 live births has an isolated cleft palate, and between 2 to 30% of patients suffer from VPI, following cleft palate repair surgery. Derek J. Lam, M.D., M.P.H., of the Cincinnati Children's Hospital Medical Center in Ohio, and his team performed a retrospective study on 73 patients with isolated cleft palates who had palate repair surgery at Seattle Children's Hospital between 2003 and 2009, at the average age of 12.5 months. The age range of all patients was 8-30 months, whilst the average follow-up time was 22 months.

Association Between Protein Aurora-A And Survival In Head And Neck Cancer

Researchers at Fox Chase Cancer Center in Philadelphia have found that a protein associated with other cancers appears to also be important in head and neck cancer, and may consequently serve as a good target for new treatments. The findings were reported at the AACR Annual Meeting. The researchers found that patients whose tumors had higher levels of the protein known as Aurora-A had a shorter survival following surgery to remove their tumors than patients whose tumors had normal levels of the protein. "This finding suggests Aurora A does play a role in the development of head and neck cancers, " says study author Christian J. Fidler, M.D., chief fellow in medical oncology at Fox Chase. "Consequently, Aurora-A represents another potential target for additional therapies." Previous research has associated Aurora-A with other cancer types, such as genitourinary, gastrointestinal, breast and lung cancers.

Productivity Losses Relating To Voice Disorder Are Comparable To Those For Chronic Diseases

Patients with voice problems have nearly as many days of short-term disability claim and work productivity losses as those with chronic conditions like asthma, heart disease and depression, according to new findings from Duke University Medical Center researchers. Per claim, voice disorders account for up to 40 lost workdays and about $3, 400 in short-term disability payments annually. "The impact of vocal disorders on work productivity has not been fully appreciated, " says Seth Cohen, M.D. an otolaryngologist at the Duke Voice Center. "This study further demonstrates the far-reaching impact they have on society." The findings were presentedat the American Laryngological Association meeting in San Diego. In recent months, well-known professional singers including John Mayer, Adele and Keith Urban have reportedly scaled back work-related responsibilities due to vocal issues.

Trials Show Promise Of Human Virus To Treat Head And Neck Cancer Patients

A naturally-occurring harmless human virus may be able to boost the effects of two standard chemotherapy drugs in some cancer patients, according to early stage trial data published in Clinical Cancer Research. RT3D, trade name Reolysin, is a new drug developed by Oncolytics Biotech Inc with preclinical and clinical studies conducted at The Institute of Cancer Research (ICR) and The Royal Marsden Hospital. It is based on a virus (reovirus type 3 Dearing) that is found in almost all adults' respiratory and gastrointestinal tracts without causing any symptoms. RT3D has the ability to grow in and kill certain types of cancer cells, but does not grow in normal cells. Previous trials injecting patients with the virus on its own showed limited effectiveness, but the team found that RT3D appeared to magnify the effects of platin and taxane-based chemotherapy on tumour cells.

Head And Neck Cancer Chemotherapy Efficacy Boosted By Human Virus

Preliminary data from a trial published in Clinical Cancer Research shows that a harmless human virus that occurs naturally could potentially boost the effects of two standard chemotherapy drugs in some cancer patients. Oncolytics Biotech Inc. developed a new drug, RT3D that will be marketed under the trade name of Reolysin. The drug is based on a virus, i.e. reovirus type 3 Dearing that is commonly found in the respiratory and gastrointestinal tracts of almost every adult without causing any symptoms. RT3D can grow and kill certain types of cancer cells, but it does not grow in normal cells. Earlier trials whereby patients were injected with only the virus displayed limited effectiveness, however, the team discovered that the effects of platin and taxane-based chemotherapy on tumor cells seemed to be magnified by RT3D.

Fast: [10] [20] [30]

Medical News © Nanda
Designer Damodar